New partnership enables a free Sesame
telehealth consultation with purchase of a Lucira at-home COVID-19
test, providing a full test-to-treat experience from the comfort of
home, within two hours
NEW YORK ,
Jan. 5,
2023 /PRNewswire/ -- Sesame, the company building a
radically new healthcare system for uninsured Americans and those
with high-deductible plans, and Lucira Health, Inc. ("Lucira
Health" or "Lucira") today announced their national partnership to
increase access to high-quality, convenient and affordable COVID-19
testing and treatment. Via Lucira Connect, a recently-launched
virtual care platform, patients who purchase Lucira's COVID-19 Test
can now easily learn about treatment options, access a free
telehealth consultation powered by Sesame, and if appropriate,
receive a prescription from the Sesame telehealth visit, all from
home for only $29 (the price of the
test)*.
Sesame is continuing to deliver on its
mission to make affordable access to everyday health care a
reality.
Lucira Connect is a user-friendly web-based platform at
www.luciraconnect.com available nationwide that begins
with self-administration of Lucira's simple at-home molecular
COVID-19 test. 98% accurate results are delivered in less than 30
minutes and users can capture their test results via their
smartphone.
If the test result is positive for COVID-19, users have the
option to book a free telehealth consultation with a Sesame
clinician within two hours to discuss their health one-on-one,
determine a treatment plan and if deemed clinically appropriate,
receive a prescription.
"With this new partnership, Sesame is continuing to deliver on
our mission to make affordable access to everyday health care a
reality," said Chase Knight, Vice
President of Business Development at Sesame. "Access to low-cost,
quick and reliable testing and treatment options for COVID-19 is
still critical for Americans, and we are honored to be doing our
part with this new partnership."
"Lucira's vision to transform at-home diagnostics and healthcare
is now a reality with this program," said Erik Engelson, President and Chief Executive
Officer at Lucira Health. "Our team has developed a platform that
delivers what consumers and the market needs to enable rapid and
effective treatment solutions for infectious diseases. The Lucira
Connect test to treat platform enables unlimited, simultaneous
rapid testing along with a treatment solution allowing individuals
to take action and get on the path to recovery fast. As Lucira
rolls out additional tests, Lucira Connect and Sesame will serve as
critical companions for users of our tests and partners to help in
their care journey."
Patients interested in purchasing a Lucira test can visit
www.lucirahealth.com/lucira-connect/ to learn more. Upon purchase,
users can navigate through Lucira Connect to access the free Sesame
telehealth visit.
About Sesame
Sesame is building a radically new healthcare system for
uninsured Americans and those with high-deductible plans. The
company's marketplace replaces historically inefficient, expensive
healthcare with a direct connection – either virtually or in-person
– between patients and physicians. This direct connection enables
Sesame to offer doctor visits, labs, imaging and prescription drugs
at half the price. Founders include a Harvard PhD in health policy
and economics; a former Goldman Sachs analyst; and entertainment
executive and healthcare reformer David
Goldhill, author of the legendary cover story in The
Atlantic, "How American Health Care Killed My Father." Sesame has
raised $75 million so far from
investors that include GV, Virgin Group and General Catalyst. The
company was ranked #1 by Healthline for overall care in 2021 and
2022. For more information, please visit www.sesamecare.com.
About Lucira Health
Lucira is a medical technology company focused on the
development and commercialization of innovative infectious disease
tests to make lab-quality diagnostics more accessible. Lucira
designed its test platform to provide accurate, reliable,
PCR-quality test results anywhere and at any time. Beyond its
already commercialized molecular COVID-19 and COVID-19 & Flu
Tests, Lucira is working on new diagnostic tests for respiratory
infections and other categories including women's health and
sexually transmitted infections (STIs). For more information,
visit www.lucirahealth.com.
Forward Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "can," "now" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements,
including but not limited to, statements regarding the accuracy of
our COVID-19 test, the demand and features of the Lucira Connect
program and our partnership with Pfizer, are based upon our current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties. These risks and
uncertainties are described more fully in the "Risk Factors"
section and elsewhere in our filings with the Securities and
Exchange Commission and available at www.sec.gov, including in our
most recent Annual Report on Form 10-K and subsequently filed
reports. Any forward-looking statements that we make in this
announcement speak only as of the date of this press release, and
we assume no obligation to update forward-looking statements
whether as a result of new information, future events or otherwise
after the date of this press release, except as required under
applicable law.
Media Contacts:
Sesame:
Liz Murphy
liz.murphy@sesamecare.com
Lucira:
media@lucirahealth.com
Lucira Investor Contact:
Investorrelations@lucirahealth.com
*Excluding any applicable prescription costs.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sesame-partners-with-lucira-health-as-official-telehealth-provider-of-lab-quality-test-to-treat-program-301713965.html
SOURCE Sesame